Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 8:7:2329048X20931361.
doi: 10.1177/2329048X20931361. eCollection 2020 Jan-Dec.

Epilepsy and EEG Phenotype of SLC13A5 Citrate Transporter Disorder

Qian-Zhou Yang  1 , Emily M Spelbrink  1 , Kimberly L Nye  2 , Emily R Hsu  2 , Brenda E Porter  1
Affiliations

Epilepsy and EEG Phenotype of SLC13A5 Citrate Transporter Disorder

Qian-Zhou Yang et al. Child Neurol Open. .

Abstract

Mutations in the SLC13A5 gene, a sodium citrate cotransporter, cause a rare autosomal recessive epilepsy (EIEE25) that begins during the neonatal period and is associated with motor and cognitive impairment. Patient's seizure burden, semiology, and electroencephalography (EEG) findings have not been well characterized. Data on 23 patients, 3 months to 29 years of age are reported. Seizures began during the neonatal period in 22 patients. Although seizures are quite severe in many patients later in life, seizure freedom was attainable in a minority of patients. Multiple patients' chronic seizure management included a few common medications, phenobarbital and valproic acid in particular. Patients EEGs had a relatively well-preserved background for age, even in the face of frequent seizures, little slowing and multiple normal EEGs and do not support an epileptic encephalopathy. Other causes for the motor and cognitive delay beyond epilepsy warrant further study.

Keywords: antiseizure drugs; developmental disability; epileptic encephalopathy; inborn errors of metabolism; neonatal seizures; seizures; status epilepticus.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Seizure semiology. The number of patients reporting each seizure semiology.
Figure 2.
Figure 2.
Electroencephalography (EEG): Normal EEG background, awake, asleep, interictal EEG, hemiclonic seizure onset. A, Normal awake background at 7 years 6 months, patient 9. B, Normal sleep architecture at 4 years 2 months, patient 10. C, Multifocal spikes with otherwise normal background at 6 years 5 months, patient 8. D, Hemiclonic seizure with head turn to the left and left more than right body jerks, with brief right-sided lead to a more generalized high-voltage spike and wave, otherwise normal awake background at 11 year 2 months, patient 2.
Figure 3.
Figure 3.
Seizure frequency. Current seizure burden.
Figure 4.
Figure 4.
Current medication usage in all patients, including the seizure-free patient subset. The current number of patients using each medication is shown in blue. The medications of those patients who are seizure free or rare yearly seizures are shown in orange.
Figure 5.
Figure 5.
Electroencephalography (EEG): Neonatal EEG background and neonatal seizure. A, Normal background on day of life 8 in patient 1, with multifocal sharps. B, Seizure onset and excessive discontinuous background on day of life 3 in patient 12.
See this image and copyright information in PMC

References

    1. Thevenon J, Milh M, Feillet F, et al. Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of life. Am J Hum Genet. 2014;95(1):113–120. - PMC - PubMed
    1. Hardies K, De Kovel CGF, Weckhuysen S, et al. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia. Brain. 2015;138(5):3238–3250. - PubMed
    1. Klotz J, Porter BE, Colas C, et al. Mutations in the Na+/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay. Mol Med. 2016;22(2):310–321. - PMC - PubMed
    1. Schossig A, Bloch-Zupan A, Lussi A, et al. SLC13A5 is the second gene associated with Kohlschütter-Tönz syndrome. J Med Genet. 2017;54(3):54–62. - PubMed
    1. Kopel JJ, Bhutia YD, Ramachandran S, et al. Opinion tooth hypoplasia for differential diagnosis of childhood epilepsy associated with SLC13A5 mutations. Int J Neurol Disord [Internet]. 2017;1(3):033–037.

LinkOut - more resources